FilingReader Intelligence

Everest Medicines invests $30.9m in I-Mab biotech stake

August 1, 2025 at 12:31 PM UTCBy FilingReader AI

Everest Medicines subscribed for 15.8 million American depositary shares of I-Mab at $1.95 per share, totaling $30.9 million.

The transaction gives Everest Medicines approximately 16.1% of I-Mab's enlarged share capital, strengthening its biopharmaceutical portfolio alongside existing products including NEFECON, XERAVA, and VELSIPITY.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Everest Medicines publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →